SCHEMBL6784255

SCHEMBL6784255

OC[C@H]1O[C@H](c2ncccc2Cl)[C@H](O)[C@@H]1O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 10/20 0.50
HIF1A Q16665 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GMNN O75496 1/20 0.45
LMNA P02545 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
STAT6 P42226 1/20 0.45
CDA P32320 1/20 0.43
PYGL P06737 2/20 0.42
SLC5A1 P13866 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790684 1.00 SLC5A2 (0.50) SLC5A2HIF1AMAPTKDM4EGMNN
SCHEMBL6790150 0.82 HIF1A (0.43) SLC5A2HIF1AMAPTCDAPYGL
SCHEMBL6790218 0.82 HIF1A (0.43) SLC5A2HIF1AMAPTCDAPYGL
SCHEMBL6785624 0.82 HIF1A (0.43) SLC5A2HIF1AMAPTCDAPYGL
SCHEMBL6790225 0.82 HIF1A (0.43) SLC5A2HIF1AMAPTCDAPYGL
SCHEMBL6789071 0.79 PYGL (0.45) SLC5A2HIF1AMAPTKDM4EGMNN
SCHEMBL6790626 0.79 PYGL (0.45) SLC5A2HIF1AMAPTKDM4EGMNN
SCHEMBL6790406 0.78 HIF1A (0.41) SLC5A2HIF1AMAPTCDAPYGL
SCHEMBL8973933 0.78 UMPS (0.43) SLC5A2HIF1AMAPTKDM4ELMNA
SCHEMBL22092162 0.78 UMPS (0.43) SLC5A2HIF1AMAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections PHARMASSET, INC. 2004-12-30 US disclosed
CN-1527836-A Antiviral agents for treatment of flaviviridae infections 2004-09-08 CN disclosed
EP-1366055-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS Pharmasset Limited (BB) 2003-12-03 EP disclosed
WO-2002048165-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS PHARMASSET LTD. (BB) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections HAVCR2, MAVS, EIF2AK2 SLC5A2 309/4885HIF1A 3985/4885MAPT 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.